Vanguard Group
VERV

Vanguard Group’s Verve Therapeutics VERV Stock Holding History

Vanguard Group’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-4,191,854
Closed -$47.1M – 4430
2025
Q2 		$47.1M Buy
4,191,854
+236,755
+6% +$1.35M ﹤0.01% 2148
2025
Q1 		$18.1M Sell
3,955,099
-51,535
-1% -$345K ﹤0.01% 2557
2024
Q4 		$22.6M Buy
4,006,634
+1,473
+0% +$8.31K ﹤0.01% 2527
2024
Q3 		$19.4M Sell
4,005,161
-1,258,348
-24% -$7.31M ﹤0.01% 2602
2024
Q2 		$25.7M Sell
5,263,509
-1,067,803
-17% -$6.71M ﹤0.01% 2451
2024
Q1 		$84.1M Buy
6,331,312
+859,382
+16% +$11.4M ﹤0.01% 1950
2023
Q4 		$76.3M Buy
5,471,930
+638,962
+13% +$7.92M ﹤0.01% 1996
2023
Q3 		$64.1M Buy
4,832,968
+741,753
+18% +$11.9M ﹤0.01% 2017
2023
Q2 		$76.7M Buy
4,091,215
+212,365
+5% +$3.54M ﹤0.01% 2001
2023
Q1 		$55.9M Buy
3,878,850
+66,826
+2% +$1.31M ﹤0.01% 2124
2022
Q4 		$73.8M Buy
3,812,024
+153,212
+4% +$4.06M ﹤0.01% 1973
2022
Q3 		$126M Buy
3,658,812
+1,316,619
+56% +$42M ﹤0.01% 1657
2022
Q2 		$35.8M Buy
2,342,193
+23,418
+1% +$363K ﹤0.01% 2348
2022
Q1 		$52.9M Buy
2,318,775
+954,554
+70% +$27.3M ﹤0.01% 2277
2021
Q4 		$50.3M Buy
1,364,221
+81,679
+6% +$3.43M ﹤0.01% 2349
2021
Q3 		$60.3M Buy
1,282,542
+1,217,542
+1,873% +$71.6M ﹤0.01% 2260
2021
Q2 		$3.92M Buy
+65,000
New +$2.7M ﹤0.01% 3715

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Vanguard Group's VERV Position: Q3 2025 in Review

Vanguard Group sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 4,191,854 shares — an estimated $47.1M sold.

Vanguard Group first reported a position in VERV in Q2 2021 and held it in 17 quarters. The position peaked at $126M in Q3 2022. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Vanguard Group reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Vanguard Group sold 4,191,854 Verve Therapeutics shares in Q3 2025, an estimated $47.1M.
  • Vanguard Group first reported a position in Verve Therapeutics in Q2 2021 and held it in 17 quarters.
  • Vanguard Group's Verve Therapeutics position peaked at $126M in Q3 2022.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Vanguard Group's 13F filing for Q3 2025, filed 7 Nov 2025.